HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.

Abstract
Objectives: The mechanism and immunoregulatory role of human natural killer (NK) cells in acute graft-vs.-host-disease (aGVHD) remains unclear. This study quantitatively analyzed the cytotoxicity of donor NK cells toward allo-reactive T cells, and investigated their relationship with acute GVHD (aGVHD). Methods: We evaluated NK dose, subgroup, and receptor expression in allografts from 98 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). A CD107a degranulating assay was used as a quantitative detection method for the cytotoxic function of donor NK cells to allo-reactive T cells. In antibody-blocking assay, NK cells were pre-treated with anti-DNAM-1(CD226), anti-NKG2D, anti-NKP46, or anti-NKG-2A monoclonal antibodies (mAbs) before the degranulating assay. Results: NK cells in allografts effectively inhibited auto-T cell proliferation following alloantigen stimulation, selectively killing alloantigen activated T cells. NKG2A- NK cell subgroups showed higher levels of CD107a degranulation toward activated T cells, when compared with NKG2A- subgroups. Blocking NKG2D or CD226 (DNAM-1) led to significant reductions in degranulation, whereas NKG2A block resulted in increased NK degranulation. Donor NK cells in the aGVHD group expressed lower levels of NKG2D and CD226, higher levels of NKG2A, and showed higher CD107a degranulation levels when compared with NK cells in the non-aGVHD group. Using univariate analysis, higher NK degranulation activities in allografts (CD107ahigh) were correlated with a decreased risk in grade I-IV aGVHD (hazard risk [HR] = 0.294; P < 0.0001), grade III-IV aGVHD (HR = 0.102; P < 0.0001), and relapse (HR = 0.157; P = 0.015), and improved overall survival (HR = 0.355; P = 0.028) after allo-HSCT. Multivariate analyses showed that higher NK degranulation activities (CD107ahigh) in allografts were independent risk factors for grades, I-IV aGVHD (HR = 0.357; P = 0.002), and grades III-IV aGVHD (HR = 0.13; P = 0.009). Conclusions: These findings reveal that the degranulation activity of NK in allografts toward allo-activated T cells was associated with the occurrence and the severity of aGVHD, after allogeneic stem cell transplantation. This suggested that cytotoxicity of donor NK cells to allo-reactive T cells have important roles in aGVHD regulation.
AuthorsLixia Sheng, Qitian Mu, Xiaoqing Wu, Shujun Yang, Huiling Zhu, Jiaping Wang, Yanli Lai, Hao Wu, Ye Sun, Yongxian Hu, Huarui Fu, Yi Wang, Kaihong Xu, Yongcheng Sun, Yanli Zhang, Ping Zhang, Miao Zhou, Binbin Lai, Zhijuan Xu, Minjie Gao, Yi Zhang, Guifang Ouyang
JournalFrontiers in immunology (Front Immunol) Vol. 11 Pg. 1534 ( 2020) ISSN: 1664-3224 [Electronic] Switzerland
PMID32849519 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Sheng, Mu, Wu, Yang, Zhu, Wang, Lai, Wu, Sun, Hu, Fu, Wang, Xu, Sun, Zhang, Zhang, Zhou, Lai, Xu, Gao, Zhang and Ouyang.
Chemical References
  • Antigens, Differentiation, T-Lymphocyte
  • Biomarkers
  • CD226 antigen
  • Isoantigens
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Antigens, Differentiation, T-Lymphocyte (immunology)
  • Biomarkers
  • Cytotoxicity, Immunologic
  • Female
  • Graft vs Host Disease (etiology, metabolism, prevention & control)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Immunophenotyping
  • Isoantigens (immunology)
  • Killer Cells, Natural (immunology, metabolism)
  • Lymphocyte Activation (immunology)
  • Male
  • Middle Aged
  • Prognosis
  • Risk Factors
  • T-Lymphocyte Subsets (immunology, metabolism)
  • Tissue Donors
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: